Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

The Next Generation of Chemotherapy-Induced Nausea and Vomiting Prevention and Control: A New 5-HT3 Antagonist Arrives

Cynthia N. Rittenberg
CJON 2004, 8(3), 307-308 DOI: 10.1188/04.CJON.307-308

First-generation serotonin receptor antagonists greatly improved the control of chemotherapy-induced nausea and vomiting (CINV) during the 1990s. A new class of agents, neurokinin-1 receptor antagonists, was introduced in March 2003 and produced even greater control of CINV when used in combination with a serotonin receptor antagonist and a corticosteroid. In July 2003, palonosetron, a new second-generation serotonin receptor antagonist that has greater potency and a longer half-life than first-generation serotonin receptor antagonists, was introduced. This clinical update reviews studies that were conducted to evaluate these new agents.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or